Aneta Mela

Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years

Aneta Mela, Łukasz A. Poniatowski, Bartłomiej Drop et al. · Frontiers in Pharmacology · 2020 · 29 citations · Full text

Public Affairs, Pharmaceutical Policy, Pharmacoeconomics +17

Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years

Aneta Mela, Elżbieta Rdzanek, Łukasz A. Poniatowski et al. · Frontiers in Pharmacology · 2020 · 28 citations · Full text

Health Professions, Cardiology, Health Sciences +17

The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology

Aneta Mela, Elżbieta Rdzanek, Andrzej Tysarowski et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2022 · 21 citations

Medicine, Health Policy, Oncology +13

The direct and indirect costs of epilepsy in Poland estimates for 2014–2016 years

Aneta Mela, Anna Staniszewska, Witold Wrona et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2018 · 11 citations

Health Professions, Health Systems, Pharmacoeconomics +13

Strontium Ranelate and Strontium Chloride Supplementation Influence on Bone Microarchitecture and Bone Turnover Markers—A Preliminary Study

Karolina Turżańska, Agnieszka Tomczyk‐Warunek, Maciej Dobrzyński et al. · Nutrients · 2023 · 10 citations · Full text

Medicine, Nutrition, Nutritional Sciences +17